Evidence map›Paper›PMID 32323293›Full record

ReviewHistology and histopathology2020

Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.

Ryan Jaques, Sam Xu, Antonios Matsakas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Histology and histopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Methanolic Leaves Extract ofInternational journal of molecular sciences · 2025
    Article
  2. Optimizing combination therapy in a murine model of HER2+ breast cancer.Computer methods in applied mechanics and engineering · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ryan JaquesCentre for Atherothrombotic and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK. hyrj5@hyms.ac.uk.
Sam XuCentre for Atherothrombotic and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK.
Antonios MatsakasCentre for Atherothrombotic and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK.

Funding

- -
6 · The paper itself

Abstract

The transmembrane oncoprotein HER2 is encoded by ERBB2 gene and overexpressed in around 20% of invasive breast cancers. It can be specifically targeted by Trastuzumab (Herceptin®), a humanised IgG1 antibody. Trastuzumab has been regarded as one of the most effective therapeutic drugs targeted to HER2 positive cancers. However, there are drawbacks, notably cardiotoxicity and resistance, which have raised awareness in clinical use. Therefore, understanding the mechanism of action is vital to establish improved therapeutic strategies. Here we evaluate Trastuzumab application in the treatment of HER2 positive breast cancer, focusing on its mechanistic actions and clinical effectiveness. Alternative therapies targeting the HER2 receptor and its downstream anomalies will also be discussed, as these could highlight further targets that could be key to improving clinical outcomes.

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalBiomarkers, TumorBreast NeoplasmsCardiotoxicityDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleHeart DiseasesHumansSignal TransductionTrastuzumabTreatment OutcomeAntineoplastic Agents, ImmunologicalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumab

Identifiers

PMID32323293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.